nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—ESR2—atherosclerosis	0.349	0.619	CbGaD
Raloxifene—ESR1—atherosclerosis	0.215	0.381	CbGaD
Raloxifene—CYP2B6—Simvastatin—atherosclerosis	0.0517	0.208	CbGbCtD
Raloxifene—CYP2C8—Simvastatin—atherosclerosis	0.0392	0.157	CbGbCtD
Raloxifene—CYP2C8—Lovastatin—atherosclerosis	0.0383	0.154	CbGbCtD
Raloxifene—CYP2C8—Pravastatin—atherosclerosis	0.0383	0.154	CbGbCtD
Raloxifene—CYP3A4—Rosuvastatin—atherosclerosis	0.0171	0.0687	CbGbCtD
Raloxifene—CYP3A4—Ezetimibe—atherosclerosis	0.0171	0.0687	CbGbCtD
Raloxifene—CYP3A4—Simvastatin—atherosclerosis	0.0159	0.0639	CbGbCtD
Raloxifene—CYP3A4—Pravastatin—atherosclerosis	0.0156	0.0625	CbGbCtD
Raloxifene—CYP3A4—Lovastatin—atherosclerosis	0.0156	0.0625	CbGbCtD
Raloxifene—Cholelithiasis—Ezetimibe—atherosclerosis	0.00191	0.0175	CcSEcCtD
Raloxifene—Gastrointestinal symptom NOS—Niacin—atherosclerosis	0.00177	0.0162	CcSEcCtD
Raloxifene—Cholelithiasis—Niacin—atherosclerosis	0.00168	0.0153	CcSEcCtD
Raloxifene—Cough increased—Rosuvastatin—atherosclerosis	0.00156	0.0143	CcSEcCtD
Raloxifene—Laryngitis—Niacin—atherosclerosis	0.00145	0.0132	CcSEcCtD
Raloxifene—Neoplasm malignant—Ezetimibe—atherosclerosis	0.00139	0.0127	CcSEcCtD
Raloxifene—Tenderness—Lovastatin—atherosclerosis	0.00139	0.0127	CcSEcCtD
Raloxifene—Tenderness—Simvastatin—atherosclerosis	0.0013	0.0119	CcSEcCtD
Raloxifene—Diabetes mellitus—Rosuvastatin—atherosclerosis	0.00119	0.0109	CcSEcCtD
Raloxifene—Breast pain—Niacin—atherosclerosis	0.00119	0.0109	CcSEcCtD
Raloxifene—Tenderness—Pravastatin—atherosclerosis	0.00118	0.0107	CcSEcCtD
Raloxifene—Gastroenteritis—Rosuvastatin—atherosclerosis	0.00117	0.0107	CcSEcCtD
Raloxifene—Cough increased—Niacin—atherosclerosis	0.00114	0.0104	CcSEcCtD
Raloxifene—Vaginal inflammation—Niacin—atherosclerosis	0.00104	0.00951	CcSEcCtD
Raloxifene—Vaginal infection—Niacin—atherosclerosis	0.000984	0.00898	CcSEcCtD
Raloxifene—Cramps of lower extremities—Niacin—atherosclerosis	0.000957	0.00874	CcSEcCtD
Raloxifene—Diabetes mellitus—Simvastatin—atherosclerosis	0.000947	0.00865	CcSEcCtD
Raloxifene—Breast disorder—Rosuvastatin—atherosclerosis	0.000939	0.00857	CcSEcCtD
Raloxifene—Hot flush—Ezetimibe—atherosclerosis	0.000924	0.00843	CcSEcCtD
Raloxifene—Menopausal symptoms—Ezetimibe—atherosclerosis	0.000916	0.00836	CcSEcCtD
Raloxifene—Arthritis—Lovastatin—atherosclerosis	0.000906	0.00827	CcSEcCtD
Raloxifene—Influenza—Rosuvastatin—atherosclerosis	0.000898	0.0082	CcSEcCtD
Raloxifene—Arthritis—Ezetimibe—atherosclerosis	0.000889	0.00812	CcSEcCtD
Raloxifene—Diabetes mellitus—Niacin—atherosclerosis	0.00087	0.00794	CcSEcCtD
Raloxifene—Bronchitis—Rosuvastatin—atherosclerosis	0.000864	0.00789	CcSEcCtD
Raloxifene—Arthritis—Simvastatin—atherosclerosis	0.000848	0.00774	CcSEcCtD
Raloxifene—Depression—Rosuvastatin—atherosclerosis	0.000799	0.00729	CcSEcCtD
Raloxifene—Hot flush—Pravastatin—atherosclerosis	0.000796	0.00727	CcSEcCtD
Raloxifene—Menopausal symptoms—Pravastatin—atherosclerosis	0.000789	0.00721	CcSEcCtD
Raloxifene—Breast disorder—Ezetimibe—atherosclerosis	0.000781	0.00713	CcSEcCtD
Raloxifene—Urinary tract infection—Rosuvastatin—atherosclerosis	0.000779	0.00711	CcSEcCtD
Raloxifene—Arthritis—Niacin—atherosclerosis	0.000778	0.00711	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Ezetimibe—atherosclerosis	0.000778	0.0071	CcSEcCtD
Raloxifene—Arthritis—Pravastatin—atherosclerosis	0.000766	0.007	CcSEcCtD
Raloxifene—Influenza—Lovastatin—atherosclerosis	0.000761	0.00695	CcSEcCtD
Raloxifene—Sinusitis—Rosuvastatin—atherosclerosis	0.000751	0.00686	CcSEcCtD
Raloxifene—Influenza—Ezetimibe—atherosclerosis	0.000747	0.00682	CcSEcCtD
Raloxifene—Migraine—Niacin—atherosclerosis	0.000745	0.0068	CcSEcCtD
Raloxifene—Rhinitis—Rosuvastatin—atherosclerosis	0.000721	0.00658	CcSEcCtD
Raloxifene—Pharyngitis—Rosuvastatin—atherosclerosis	0.000714	0.00651	CcSEcCtD
Raloxifene—Bronchitis—Simvastatin—atherosclerosis	0.000685	0.00625	CcSEcCtD
Raloxifene—Urinary tract infection—Lovastatin—atherosclerosis	0.00066	0.00602	CcSEcCtD
Raloxifene—Influenza—Niacin—atherosclerosis	0.000654	0.00597	CcSEcCtD
Raloxifene—Influenza—Pravastatin—atherosclerosis	0.000644	0.00588	CcSEcCtD
Raloxifene—Sinusitis—Lovastatin—atherosclerosis	0.000637	0.00581	CcSEcCtD
Raloxifene—Depression—Simvastatin—atherosclerosis	0.000633	0.00578	CcSEcCtD
Raloxifene—Bronchitis—Niacin—atherosclerosis	0.000629	0.00574	CcSEcCtD
Raloxifene—Sinusitis—Ezetimibe—atherosclerosis	0.000625	0.0057	CcSEcCtD
Raloxifene—Flatulence—Rosuvastatin—atherosclerosis	0.000617	0.00563	CcSEcCtD
Raloxifene—Sinusitis—Simvastatin—atherosclerosis	0.000596	0.00544	CcSEcCtD
Raloxifene—Pharyngitis—Ezetimibe—atherosclerosis	0.000593	0.00542	CcSEcCtD
Raloxifene—Oedema peripheral—Ezetimibe—atherosclerosis	0.000589	0.00538	CcSEcCtD
Raloxifene—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000587	0.00536	CcSEcCtD
Raloxifene—Weight increased—Pravastatin—atherosclerosis	0.000586	0.00535	CcSEcCtD
Raloxifene—Depression—Pravastatin—atherosclerosis	0.000572	0.00523	CcSEcCtD
Raloxifene—Flushing—Lovastatin—atherosclerosis	0.000566	0.00516	CcSEcCtD
Raloxifene—Sweating—Niacin—atherosclerosis	0.000559	0.0051	CcSEcCtD
Raloxifene—Urinary tract infection—Pravastatin—atherosclerosis	0.000558	0.00509	CcSEcCtD
Raloxifene—Flushing—Ezetimibe—atherosclerosis	0.000555	0.00506	CcSEcCtD
Raloxifene—Cough—Rosuvastatin—atherosclerosis	0.000546	0.00499	CcSEcCtD
Raloxifene—Angiopathy—Ezetimibe—atherosclerosis	0.000542	0.00495	CcSEcCtD
Raloxifene—Sinusitis—Pravastatin—atherosclerosis	0.000539	0.00492	CcSEcCtD
Raloxifene—Myalgia—Rosuvastatin—atherosclerosis	0.000533	0.00486	CcSEcCtD
Raloxifene—Arthralgia—Rosuvastatin—atherosclerosis	0.000533	0.00486	CcSEcCtD
Raloxifene—Flushing—Simvastatin—atherosclerosis	0.000529	0.00483	CcSEcCtD
Raloxifene—Rhinitis—Niacin—atherosclerosis	0.000525	0.00479	CcSEcCtD
Raloxifene—Flatulence—Lovastatin—atherosclerosis	0.000523	0.00477	CcSEcCtD
Raloxifene—Hypoaesthesia—Niacin—atherosclerosis	0.000521	0.00475	CcSEcCtD
Raloxifene—Rhinitis—Pravastatin—atherosclerosis	0.000517	0.00472	CcSEcCtD
Raloxifene—Oedema peripheral—Niacin—atherosclerosis	0.000516	0.00471	CcSEcCtD
Raloxifene—Hypoaesthesia—Pravastatin—atherosclerosis	0.000513	0.00468	CcSEcCtD
Raloxifene—Flatulence—Ezetimibe—atherosclerosis	0.000513	0.00468	CcSEcCtD
Raloxifene—Pharyngitis—Pravastatin—atherosclerosis	0.000511	0.00467	CcSEcCtD
Raloxifene—Muscle spasms—Lovastatin—atherosclerosis	0.00051	0.00466	CcSEcCtD
Raloxifene—Infection—Rosuvastatin—atherosclerosis	0.000508	0.00463	CcSEcCtD
Raloxifene—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000501	0.00457	CcSEcCtD
Raloxifene—Muscle spasms—Ezetimibe—atherosclerosis	0.0005	0.00457	CcSEcCtD
Raloxifene—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.0005	0.00457	CcSEcCtD
Raloxifene—Flatulence—Simvastatin—atherosclerosis	0.000489	0.00446	CcSEcCtD
Raloxifene—Flushing—Niacin—atherosclerosis	0.000486	0.00443	CcSEcCtD
Raloxifene—Flushing—Pravastatin—atherosclerosis	0.000478	0.00437	CcSEcCtD
Raloxifene—Cardiac disorder—Pravastatin—atherosclerosis	0.000478	0.00437	CcSEcCtD
Raloxifene—Muscle spasms—Simvastatin—atherosclerosis	0.000477	0.00435	CcSEcCtD
Raloxifene—Vertigo—Lovastatin—atherosclerosis	0.000477	0.00435	CcSEcCtD
Raloxifene—Angiopathy—Niacin—atherosclerosis	0.000475	0.00433	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000465	0.00425	CcSEcCtD
Raloxifene—Insomnia—Rosuvastatin—atherosclerosis	0.000462	0.00422	CcSEcCtD
Raloxifene—Cough—Ezetimibe—atherosclerosis	0.000454	0.00414	CcSEcCtD
Raloxifene—Chest pain—Lovastatin—atherosclerosis	0.000452	0.00412	CcSEcCtD
Raloxifene—Myalgia—Lovastatin—atherosclerosis	0.000452	0.00412	CcSEcCtD
Raloxifene—Arthralgia—Lovastatin—atherosclerosis	0.000452	0.00412	CcSEcCtD
Raloxifene—Dyspepsia—Rosuvastatin—atherosclerosis	0.00045	0.00411	CcSEcCtD
Raloxifene—Flatulence—Niacin—atherosclerosis	0.000449	0.0041	CcSEcCtD
Raloxifene—Vertigo—Simvastatin—atherosclerosis	0.000446	0.00407	CcSEcCtD
Raloxifene—Arthralgia—Ezetimibe—atherosclerosis	0.000443	0.00404	CcSEcCtD
Raloxifene—Chest pain—Ezetimibe—atherosclerosis	0.000443	0.00404	CcSEcCtD
Raloxifene—Myalgia—Ezetimibe—atherosclerosis	0.000443	0.00404	CcSEcCtD
Raloxifene—Flatulence—Pravastatin—atherosclerosis	0.000442	0.00404	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00044	0.00402	CcSEcCtD
Raloxifene—Muscle spasms—Niacin—atherosclerosis	0.000438	0.004	CcSEcCtD
Raloxifene—Pain—Rosuvastatin—atherosclerosis	0.000437	0.00399	CcSEcCtD
Raloxifene—Muscle spasms—Pravastatin—atherosclerosis	0.000431	0.00394	CcSEcCtD
Raloxifene—Infection—Lovastatin—atherosclerosis	0.00043	0.00393	CcSEcCtD
Raloxifene—Thrombocytopenia—Lovastatin—atherosclerosis	0.000424	0.00387	CcSEcCtD
Raloxifene—Myalgia—Simvastatin—atherosclerosis	0.000422	0.00386	CcSEcCtD
Raloxifene—Chest pain—Simvastatin—atherosclerosis	0.000422	0.00386	CcSEcCtD
Raloxifene—Arthralgia—Simvastatin—atherosclerosis	0.000422	0.00386	CcSEcCtD
Raloxifene—Infection—Ezetimibe—atherosclerosis	0.000422	0.00385	CcSEcCtD
Raloxifene—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000418	0.00381	CcSEcCtD
Raloxifene—Nervous system disorder—Ezetimibe—atherosclerosis	0.000416	0.0038	CcSEcCtD
Raloxifene—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000416	0.0038	CcSEcCtD
Raloxifene—Skin disorder—Ezetimibe—atherosclerosis	0.000412	0.00377	CcSEcCtD
Raloxifene—Vertigo—Niacin—atherosclerosis	0.000409	0.00374	CcSEcCtD
Raloxifene—Syncope—Niacin—atherosclerosis	0.000409	0.00373	CcSEcCtD
Raloxifene—Abdominal pain—Rosuvastatin—atherosclerosis	0.000404	0.00369	CcSEcCtD
Raloxifene—Vertigo—Pravastatin—atherosclerosis	0.000403	0.00368	CcSEcCtD
Raloxifene—Infection—Simvastatin—atherosclerosis	0.000402	0.00367	CcSEcCtD
Raloxifene—Loss of consciousness—Niacin—atherosclerosis	0.0004	0.00366	CcSEcCtD
Raloxifene—Cough—Niacin—atherosclerosis	0.000398	0.00363	CcSEcCtD
Raloxifene—Thrombocytopenia—Simvastatin—atherosclerosis	0.000396	0.00362	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000394	0.0036	CcSEcCtD
Raloxifene—Insomnia—Lovastatin—atherosclerosis	0.000392	0.00357	CcSEcCtD
Raloxifene—Cough—Pravastatin—atherosclerosis	0.000391	0.00357	CcSEcCtD
Raloxifene—Arthralgia—Niacin—atherosclerosis	0.000388	0.00354	CcSEcCtD
Raloxifene—Myalgia—Niacin—atherosclerosis	0.000388	0.00354	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000387	0.00353	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000385	0.00352	CcSEcCtD
Raloxifene—Insomnia—Ezetimibe—atherosclerosis	0.000384	0.00351	CcSEcCtD
Raloxifene—Arthralgia—Pravastatin—atherosclerosis	0.000382	0.00349	CcSEcCtD
Raloxifene—Chest pain—Pravastatin—atherosclerosis	0.000382	0.00349	CcSEcCtD
Raloxifene—Myalgia—Pravastatin—atherosclerosis	0.000382	0.00349	CcSEcCtD
Raloxifene—Dyspepsia—Lovastatin—atherosclerosis	0.000381	0.00348	CcSEcCtD
Raloxifene—Dyspepsia—Ezetimibe—atherosclerosis	0.000374	0.00341	CcSEcCtD
Raloxifene—Pain—Lovastatin—atherosclerosis	0.00037	0.00338	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000369	0.00337	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000367	0.00335	CcSEcCtD
Raloxifene—Insomnia—Simvastatin—atherosclerosis	0.000366	0.00334	CcSEcCtD
Raloxifene—Shock—Niacin—atherosclerosis	0.000366	0.00334	CcSEcCtD
Raloxifene—Infection—Pravastatin—atherosclerosis	0.000364	0.00332	CcSEcCtD
Raloxifene—Pain—Ezetimibe—atherosclerosis	0.000363	0.00331	CcSEcCtD
Raloxifene—Skin disorder—Niacin—atherosclerosis	0.000361	0.0033	CcSEcCtD
Raloxifene—Hyperhidrosis—Niacin—atherosclerosis	0.000359	0.00328	CcSEcCtD
Raloxifene—Thrombocytopenia—Pravastatin—atherosclerosis	0.000358	0.00327	CcSEcCtD
Raloxifene—Dyspepsia—Simvastatin—atherosclerosis	0.000356	0.00325	CcSEcCtD
Raloxifene—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000354	0.00323	CcSEcCtD
Raloxifene—Hyperhidrosis—Pravastatin—atherosclerosis	0.000354	0.00323	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00035	0.00319	CcSEcCtD
Raloxifene—Diarrhoea—Rosuvastatin—atherosclerosis	0.00035	0.00319	CcSEcCtD
Raloxifene—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000347	0.00317	CcSEcCtD
Raloxifene—Pain—Simvastatin—atherosclerosis	0.000346	0.00316	CcSEcCtD
Raloxifene—Abdominal pain—Lovastatin—atherosclerosis	0.000342	0.00312	CcSEcCtD
Raloxifene—Body temperature increased—Lovastatin—atherosclerosis	0.000342	0.00312	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000339	0.00309	CcSEcCtD
Raloxifene—Dizziness—Rosuvastatin—atherosclerosis	0.000338	0.00308	CcSEcCtD
Raloxifene—Insomnia—Niacin—atherosclerosis	0.000336	0.00307	CcSEcCtD
Raloxifene—Body temperature increased—Ezetimibe—atherosclerosis	0.000336	0.00306	CcSEcCtD
Raloxifene—Abdominal pain—Ezetimibe—atherosclerosis	0.000336	0.00306	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000334	0.00305	CcSEcCtD
Raloxifene—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000331	0.00302	CcSEcCtD
Raloxifene—Insomnia—Pravastatin—atherosclerosis	0.000331	0.00302	CcSEcCtD
Raloxifene—Dyspepsia—Niacin—atherosclerosis	0.000327	0.00299	CcSEcCtD
Raloxifene—Dyspepsia—Pravastatin—atherosclerosis	0.000322	0.00294	CcSEcCtD
Raloxifene—Rash—Rosuvastatin—atherosclerosis	0.000322	0.00294	CcSEcCtD
Raloxifene—Dermatitis—Rosuvastatin—atherosclerosis	0.000322	0.00294	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Niacin—atherosclerosis	0.000321	0.00293	CcSEcCtD
Raloxifene—Abdominal pain—Simvastatin—atherosclerosis	0.00032	0.00292	CcSEcCtD
Raloxifene—Body temperature increased—Simvastatin—atherosclerosis	0.00032	0.00292	CcSEcCtD
Raloxifene—Headache—Rosuvastatin—atherosclerosis	0.00032	0.00292	CcSEcCtD
Raloxifene—Pain—Niacin—atherosclerosis	0.000318	0.0029	CcSEcCtD
Raloxifene—Pain—Pravastatin—atherosclerosis	0.000313	0.00286	CcSEcCtD
Raloxifene—Gastrointestinal pain—Niacin—atherosclerosis	0.000304	0.00278	CcSEcCtD
Raloxifene—Nausea—Rosuvastatin—atherosclerosis	0.000303	0.00277	CcSEcCtD
Raloxifene—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000299	0.00273	CcSEcCtD
Raloxifene—Diarrhoea—Lovastatin—atherosclerosis	0.000296	0.0027	CcSEcCtD
Raloxifene—Abdominal pain—Niacin—atherosclerosis	0.000294	0.00268	CcSEcCtD
Raloxifene—Body temperature increased—Niacin—atherosclerosis	0.000294	0.00268	CcSEcCtD
Raloxifene—Diarrhoea—Ezetimibe—atherosclerosis	0.000291	0.00265	CcSEcCtD
Raloxifene—Body temperature increased—Pravastatin—atherosclerosis	0.000289	0.00264	CcSEcCtD
Raloxifene—Abdominal pain—Pravastatin—atherosclerosis	0.000289	0.00264	CcSEcCtD
Raloxifene—Dizziness—Lovastatin—atherosclerosis	0.000286	0.00261	CcSEcCtD
Raloxifene—Dizziness—Ezetimibe—atherosclerosis	0.000281	0.00256	CcSEcCtD
Raloxifene—Diarrhoea—Simvastatin—atherosclerosis	0.000277	0.00253	CcSEcCtD
Raloxifene—Vomiting—Lovastatin—atherosclerosis	0.000275	0.00251	CcSEcCtD
Raloxifene—Rash—Lovastatin—atherosclerosis	0.000273	0.00249	CcSEcCtD
Raloxifene—Dermatitis—Lovastatin—atherosclerosis	0.000273	0.00249	CcSEcCtD
Raloxifene—Headache—Lovastatin—atherosclerosis	0.000271	0.00248	CcSEcCtD
Raloxifene—Vomiting—Ezetimibe—atherosclerosis	0.00027	0.00246	CcSEcCtD
Raloxifene—Dizziness—Simvastatin—atherosclerosis	0.000268	0.00244	CcSEcCtD
Raloxifene—Rash—Ezetimibe—atherosclerosis	0.000268	0.00244	CcSEcCtD
Raloxifene—Dermatitis—Ezetimibe—atherosclerosis	0.000267	0.00244	CcSEcCtD
Raloxifene—Headache—Ezetimibe—atherosclerosis	0.000266	0.00243	CcSEcCtD
Raloxifene—Vomiting—Simvastatin—atherosclerosis	0.000257	0.00235	CcSEcCtD
Raloxifene—Nausea—Lovastatin—atherosclerosis	0.000257	0.00235	CcSEcCtD
Raloxifene—Rash—Simvastatin—atherosclerosis	0.000255	0.00233	CcSEcCtD
Raloxifene—Dermatitis—Simvastatin—atherosclerosis	0.000255	0.00233	CcSEcCtD
Raloxifene—Diarrhoea—Niacin—atherosclerosis	0.000254	0.00232	CcSEcCtD
Raloxifene—Headache—Simvastatin—atherosclerosis	0.000254	0.00232	CcSEcCtD
Raloxifene—Nausea—Ezetimibe—atherosclerosis	0.000252	0.0023	CcSEcCtD
Raloxifene—Diarrhoea—Pravastatin—atherosclerosis	0.00025	0.00229	CcSEcCtD
Raloxifene—Dizziness—Niacin—atherosclerosis	0.000246	0.00224	CcSEcCtD
Raloxifene—Dizziness—Pravastatin—atherosclerosis	0.000242	0.00221	CcSEcCtD
Raloxifene—Nausea—Simvastatin—atherosclerosis	0.000241	0.0022	CcSEcCtD
Raloxifene—Vomiting—Niacin—atherosclerosis	0.000236	0.00216	CcSEcCtD
Raloxifene—Rash—Niacin—atherosclerosis	0.000234	0.00214	CcSEcCtD
Raloxifene—Dermatitis—Niacin—atherosclerosis	0.000234	0.00214	CcSEcCtD
Raloxifene—Headache—Niacin—atherosclerosis	0.000233	0.00213	CcSEcCtD
Raloxifene—Vomiting—Pravastatin—atherosclerosis	0.000233	0.00213	CcSEcCtD
Raloxifene—Rash—Pravastatin—atherosclerosis	0.000231	0.00211	CcSEcCtD
Raloxifene—Dermatitis—Pravastatin—atherosclerosis	0.000231	0.00211	CcSEcCtD
Raloxifene—Headache—Pravastatin—atherosclerosis	0.000229	0.00209	CcSEcCtD
Raloxifene—Nausea—Niacin—atherosclerosis	0.000221	0.00202	CcSEcCtD
Raloxifene—Nausea—Pravastatin—atherosclerosis	0.000217	0.00199	CcSEcCtD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	1.2e-05	0.000155	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PARP1—atherosclerosis	1.2e-05	0.000155	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—GHRL—atherosclerosis	1.2e-05	0.000155	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PLAT—atherosclerosis	1.2e-05	0.000155	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—LDLR—atherosclerosis	1.19e-05	0.000154	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PLA2G1B—atherosclerosis	1.19e-05	0.000154	CbGpPWpGaD
Raloxifene—AOX1—Disease—STAT3—atherosclerosis	1.19e-05	0.000154	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—APOB—atherosclerosis	1.18e-05	0.000153	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.17e-05	0.000152	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—CXCL8—atherosclerosis	1.17e-05	0.000152	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GSTM1—atherosclerosis	1.17e-05	0.000151	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—PPARA—atherosclerosis	1.17e-05	0.000151	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CETP—atherosclerosis	1.16e-05	0.000151	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EDN1—atherosclerosis	1.16e-05	0.000151	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.16e-05	0.000151	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.16e-05	0.00015	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SOCS3—atherosclerosis	1.16e-05	0.00015	CbGpPWpGaD
Raloxifene—EBP—Metabolism—AKT1—atherosclerosis	1.16e-05	0.00015	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CCL5—atherosclerosis	1.16e-05	0.00015	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ABCG8—atherosclerosis	1.15e-05	0.000149	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—LTA4H—atherosclerosis	1.15e-05	0.000149	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—LPL—atherosclerosis	1.15e-05	0.000149	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ALOX5—atherosclerosis	1.15e-05	0.000149	CbGpPWpGaD
Raloxifene—AOX1—Disease—MAPK3—atherosclerosis	1.13e-05	0.000147	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—LPL—atherosclerosis	1.13e-05	0.000146	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—MAPK3—atherosclerosis	1.12e-05	0.000145	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GPX1—atherosclerosis	1.12e-05	0.000145	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MMP3—atherosclerosis	1.12e-05	0.000145	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—SCARB1—atherosclerosis	1.12e-05	0.000144	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IGF2—atherosclerosis	1.11e-05	0.000144	CbGpPWpGaD
Raloxifene—AOX1—Disease—TGFB1—atherosclerosis	1.1e-05	0.000142	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PRKCG—atherosclerosis	1.1e-05	0.000142	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CD36—atherosclerosis	1.09e-05	0.000141	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—APOB—atherosclerosis	1.08e-05	0.00014	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—CXCL8—atherosclerosis	1.07e-05	0.000139	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SPP1—atherosclerosis	1.07e-05	0.000139	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—CXCL8—atherosclerosis	1.06e-05	0.000138	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EDN1—atherosclerosis	1.06e-05	0.000138	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.06e-05	0.000137	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CCL5—atherosclerosis	1.05e-05	0.000137	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—HMGCR—atherosclerosis	1.05e-05	0.000136	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KNG1—atherosclerosis	1.05e-05	0.000136	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AGTR1—atherosclerosis	1.04e-05	0.000135	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—MTHFR—atherosclerosis	1.03e-05	0.000134	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—LPL—atherosclerosis	1.03e-05	0.000134	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NAMPT—atherosclerosis	1.03e-05	0.000133	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.02e-05	0.000132	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—LIPC—atherosclerosis	1.02e-05	0.000132	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PLG—atherosclerosis	1.02e-05	0.000132	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—APOC3—atherosclerosis	1.02e-05	0.000132	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PPARA—atherosclerosis	1.01e-05	0.000131	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—LDLR—atherosclerosis	1.01e-05	0.000131	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PRKCG—atherosclerosis	1e-05	0.00013	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PDGFB—atherosclerosis	9.9e-06	0.000128	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CETP—atherosclerosis	9.86e-06	0.000128	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—AGT—atherosclerosis	9.81e-06	0.000127	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SPP1—atherosclerosis	9.76e-06	0.000126	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—CXCL8—atherosclerosis	9.72e-06	0.000126	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AGT—atherosclerosis	9.66e-06	0.000125	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—PPARG—atherosclerosis	9.64e-06	0.000125	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SOCS3—atherosclerosis	9.63e-06	0.000125	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—APOE—atherosclerosis	9.62e-06	0.000125	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CAV1—atherosclerosis	9.53e-06	0.000123	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—APOA1—atherosclerosis	9.51e-06	0.000123	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—LEP—atherosclerosis	9.47e-06	0.000123	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—APOE—atherosclerosis	9.47e-06	0.000123	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SCARB1—atherosclerosis	9.44e-06	0.000122	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ABCA1—atherosclerosis	9.39e-06	0.000122	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CAV1—atherosclerosis	9.38e-06	0.000122	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—APOA1—atherosclerosis	9.36e-06	0.000121	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MMP3—atherosclerosis	9.31e-06	0.000121	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IGF2—atherosclerosis	9.26e-06	0.00012	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	9.19e-06	0.000119	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ABCG1—atherosclerosis	9.11e-06	0.000118	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ESR1—atherosclerosis	9.04e-06	0.000117	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PDGFB—atherosclerosis	9.03e-06	0.000117	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—APOB—atherosclerosis	8.99e-06	0.000117	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—F2—atherosclerosis	8.93e-06	0.000116	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—HMGCR—atherosclerosis	8.92e-06	0.000116	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EDN1—atherosclerosis	8.85e-06	0.000115	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AGT—atherosclerosis	8.82e-06	0.000114	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CCL5—atherosclerosis	8.78e-06	0.000114	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—SERPINE1—atherosclerosis	8.69e-06	0.000113	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CG—atherosclerosis	8.68e-06	0.000112	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—APOE—atherosclerosis	8.64e-06	0.000112	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—LEP—atherosclerosis	8.64e-06	0.000112	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—LPL—atherosclerosis	8.59e-06	0.000111	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—LCAT—atherosclerosis	8.57e-06	0.000111	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—FABP4—atherosclerosis	8.57e-06	0.000111	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CAV1—atherosclerosis	8.56e-06	0.000111	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CG—atherosclerosis	8.54e-06	0.000111	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—APOA1—atherosclerosis	8.54e-06	0.000111	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—APOA4—atherosclerosis	8.41e-06	0.000109	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PPARG—atherosclerosis	8.38e-06	0.000109	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PRKCG—atherosclerosis	8.35e-06	0.000108	CbGpPWpGaD
Raloxifene—AOX1—Disease—IL6—atherosclerosis	8.29e-06	0.000107	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP7A1—atherosclerosis	8.26e-06	0.000107	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ESR1—atherosclerosis	8.25e-06	0.000107	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—INS—atherosclerosis	8.21e-06	0.000106	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—MAPK3—atherosclerosis	8.18e-06	0.000106	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—F2—atherosclerosis	8.15e-06	0.000106	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SPP1—atherosclerosis	8.13e-06	0.000105	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—INS—atherosclerosis	8.09e-06	0.000105	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—HMOX1—atherosclerosis	8.06e-06	0.000104	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	8.04e-06	0.000104	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CCL2—atherosclerosis	7.96e-06	0.000103	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ABCA1—atherosclerosis	7.95e-06	0.000103	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IGF1—atherosclerosis	7.82e-06	0.000101	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CG—atherosclerosis	7.8e-06	0.000101	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—APOB—atherosclerosis	7.72e-06	0.0001	CbGpPWpGaD
Raloxifene—AOX1—Disease—AKT1—atherosclerosis	7.65e-06	9.91e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP27A1—atherosclerosis	7.64e-06	9.89e-05	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—AKT1—atherosclerosis	7.56e-06	9.79e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ALB—atherosclerosis	7.53e-06	9.76e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PDGFB—atherosclerosis	7.53e-06	9.75e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTM1—atherosclerosis	7.51e-06	9.72e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—MAPK3—atherosclerosis	7.47e-06	9.68e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SERPINE1—atherosclerosis	7.43e-06	9.62e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—INS—atherosclerosis	7.38e-06	9.56e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—LPL—atherosclerosis	7.37e-06	9.54e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AGT—atherosclerosis	7.35e-06	9.52e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CCL2—atherosclerosis	7.26e-06	9.41e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—APOA2—atherosclerosis	7.24e-06	9.38e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	7.24e-06	9.38e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	7.24e-06	9.38e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ALOX15—atherosclerosis	7.24e-06	9.38e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—NOS3—atherosclerosis	7.2e-06	9.33e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—APOE—atherosclerosis	7.2e-06	9.32e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—LEP—atherosclerosis	7.2e-06	9.32e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GPX1—atherosclerosis	7.19e-06	9.31e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ABCG5—atherosclerosis	7.15e-06	9.26e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IGF1—atherosclerosis	7.14e-06	9.25e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CAV1—atherosclerosis	7.13e-06	9.24e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—APOA1—atherosclerosis	7.12e-06	9.22e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NOS3—atherosclerosis	7.09e-06	9.19e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CD36—atherosclerosis	7e-06	9.07e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—LPA—atherosclerosis	6.91e-06	8.95e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—HMOX1—atherosclerosis	6.82e-06	8.83e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—F2—atherosclerosis	6.79e-06	8.79e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SERPINE1—atherosclerosis	6.78e-06	8.78e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—BGN—atherosclerosis	6.69e-06	8.66e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—MTHFR—atherosclerosis	6.63e-06	8.59e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—APOA5—atherosclerosis	6.62e-06	8.58e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTGS2—atherosclerosis	6.59e-06	8.54e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—APOB—atherosclerosis	6.53e-06	8.46e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PPARA—atherosclerosis	6.51e-06	8.43e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CG—atherosclerosis	6.5e-06	8.42e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NOS3—atherosclerosis	6.47e-06	8.39e-05	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—AKT1—atherosclerosis	6.4e-06	8.3e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	6.37e-06	8.26e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTM1—atherosclerosis	6.35e-06	8.23e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—AGT—atherosclerosis	6.3e-06	8.16e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CXCL8—atherosclerosis	6.29e-06	8.15e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—LPL—atherosclerosis	6.24e-06	8.08e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—APOE—atherosclerosis	6.18e-06	8e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ALOX5—atherosclerosis	6.16e-06	7.97e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—INS—atherosclerosis	6.15e-06	7.97e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CAV1—atherosclerosis	6.12e-06	7.93e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—APOA1—atherosclerosis	6.1e-06	7.91e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GPX1—atherosclerosis	6.09e-06	7.88e-05	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—AKT1—atherosclerosis	6.08e-06	7.87e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CCL2—atherosclerosis	6.05e-06	7.84e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—IL6—atherosclerosis	5.98e-06	7.75e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IGF1—atherosclerosis	5.95e-06	7.71e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CD36—atherosclerosis	5.93e-06	7.68e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CXCL8—atherosclerosis	5.74e-06	7.44e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MMP9—atherosclerosis	5.69e-06	7.37e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MAPK3—atherosclerosis	5.65e-06	7.32e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SERPINE1—atherosclerosis	5.65e-06	7.32e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NFKB1—atherosclerosis	5.63e-06	7.29e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—MTHFR—atherosclerosis	5.62e-06	7.27e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CG—atherosclerosis	5.57e-06	7.22e-05	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—AKT1—atherosclerosis	5.55e-06	7.19e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MAPK8—atherosclerosis	5.53e-06	7.17e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NAMPT—atherosclerosis	5.52e-06	7.15e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—AKT1—atherosclerosis	5.52e-06	7.15e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PPARA—atherosclerosis	5.51e-06	7.14e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—LIPC—atherosclerosis	5.49e-06	7.11e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—IL6—atherosclerosis	5.46e-06	7.07e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—APOC3—atherosclerosis	5.45e-06	7.06e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—LDLR—atherosclerosis	5.42e-06	7.02e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NOS3—atherosclerosis	5.39e-06	6.99e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PPARG—atherosclerosis	5.38e-06	6.97e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—AGT—atherosclerosis	5.34e-06	6.91e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CETP—atherosclerosis	5.29e-06	6.86e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—INS—atherosclerosis	5.28e-06	6.83e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—APOE—atherosclerosis	5.23e-06	6.77e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MMP9—atherosclerosis	5.19e-06	6.73e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CAV1—atherosclerosis	5.18e-06	6.71e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—APOA1—atherosclerosis	5.17e-06	6.7e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NFKB1—atherosclerosis	5.14e-06	6.66e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—VEGFA—atherosclerosis	5.11e-06	6.62e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SCARB1—atherosclerosis	5.07e-06	6.57e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—STAT3—atherosclerosis	5.06e-06	6.55e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAPK8—atherosclerosis	5.05e-06	6.54e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—AKT1—atherosclerosis	5.04e-06	6.53e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ALB—atherosclerosis	4.84e-06	6.27e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MAPK3—atherosclerosis	4.83e-06	6.26e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—HMGCR—atherosclerosis	4.79e-06	6.2e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CXCL8—atherosclerosis	4.78e-06	6.2e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CG—atherosclerosis	4.72e-06	6.11e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TGFB1—atherosclerosis	4.69e-06	6.08e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	4.66e-06	6.04e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—NOS3—atherosclerosis	4.63e-06	5.99e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—STAT3—atherosclerosis	4.62e-06	5.98e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PPARG—atherosclerosis	4.55e-06	5.9e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—INS—atherosclerosis	4.47e-06	5.79e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	4.41e-06	5.72e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MMP9—atherosclerosis	4.33e-06	5.6e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NFKB1—atherosclerosis	4.28e-06	5.55e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	4.28e-06	5.55e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ABCA1—atherosclerosis	4.27e-06	5.53e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTGS2—atherosclerosis	4.23e-06	5.48e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAPK8—atherosclerosis	4.21e-06	5.45e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ALB—atherosclerosis	4.09e-06	5.3e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NOS3—atherosclerosis	3.92e-06	5.07e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—VEGFA—atherosclerosis	3.89e-06	5.03e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—STAT3—atherosclerosis	3.85e-06	4.98e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—AKT1—atherosclerosis	3.81e-06	4.94e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAPK3—atherosclerosis	3.68e-06	4.76e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—HMOX1—atherosclerosis	3.66e-06	4.74e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTGS2—atherosclerosis	3.58e-06	4.64e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TGFB1—atherosclerosis	3.57e-06	4.62e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL6—atherosclerosis	3.53e-06	4.58e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—APOB—atherosclerosis	3.51e-06	4.54e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTM1—atherosclerosis	3.41e-06	4.42e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—LPL—atherosclerosis	3.35e-06	4.34e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—AKT1—atherosclerosis	3.31e-06	4.29e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GPX1—atherosclerosis	3.27e-06	4.23e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AKT1—atherosclerosis	3.26e-06	4.22e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL6—atherosclerosis	3.23e-06	4.18e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CD36—atherosclerosis	3.18e-06	4.12e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.01e-06	3.9e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AKT1—atherosclerosis	2.98e-06	3.86e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PPARA—atherosclerosis	2.96e-06	3.83e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AGT—atherosclerosis	2.86e-06	3.71e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—APOE—atherosclerosis	2.81e-06	3.64e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CAV1—atherosclerosis	2.78e-06	3.6e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—APOA1—atherosclerosis	2.77e-06	3.59e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL6—atherosclerosis	2.69e-06	3.48e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.53e-06	3.28e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AKT1—atherosclerosis	2.48e-06	3.21e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PPARG—atherosclerosis	2.44e-06	3.17e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—INS—atherosclerosis	2.4e-06	3.11e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ALB—atherosclerosis	2.2e-06	2.85e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—AKT1—atherosclerosis	2.13e-06	2.75e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NOS3—atherosclerosis	2.1e-06	2.72e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.92e-06	2.49e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—AKT1—atherosclerosis	1.8e-06	2.33e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AKT1—atherosclerosis	9.66e-07	1.25e-05	CbGpPWpGaD
